Helus Pharma Partners with TARA Mind for Phase 3 HLP003 Trial Recruitment in Veterans

Helus Pharma (formerly Cybin Inc.) announced a strategic collaboration with TARA Mind to support recruitment for its ongoing PARADIGM Phase 3 clinical trial of HLP003. HLP003 is a proprietary novel serotonergic agonist (NSA) being developed for the adjunctive treatment of Major Depressive Disorder (MDD) and has received FDA Breakthrough Therapy Designation. The partnership aims to leverage TARA Mind’s network and its work with Veterans Exploring Treatment Solutions (VETS) to expand mental health outreach and clinical trial access specifically within the veteran community. This initiative aligns with a recent U.S. Executive Order focused on accelerating medical treatments for serious mental illness. By targeting veterans—a population with high rates of depression and PTSD—the company intends to streamline enrollment for its late-stage HLP003 program while fulfilling broader public health priorities. Helus Pharma is also currently advancing HLP004 in Phase 2 development for generalized anxiety disorder.